▁In 4.93359375
▁a 2.85546875
▁prom 8.2109375
ising 0.51220703125
▁development 1.603515625
▁in 2.748046875
▁the 0.5068359375
▁field 2.697265625
▁of 0.02203369140625
▁on 6.33203125
col 0.336669921875
ogy 0.062744140625
, 0.1363525390625
▁the 2.26171875
▁British 6.54296875
▁bi 2.978515625
ote 0.311767578125
chn 0.82666015625
ology 0.0166015625
▁firm 1.701171875
, 2.169921875
▁British 9.15625
▁Bi 0.75146484375
ote 0.0380859375
ch 0.09375
, 1.0712890625
▁has 0.6640625
▁announced 1.2294921875
▁that 0.7099609375
▁its 1.7021484375
▁ground 4.73046875
bre 0.68994140625
aking 9.381771087646484e-05
▁anti 3.4921875
- 0.01503753662109375
can 0.2091064453125
cer 0.00027871131896972656
▁treatment 2.515625
, 0.7587890625
▁Mar 6.96484375
im 4.11328125
ast 0.393798828125
at 0.0027313232421875
, 0.1395263671875
▁will 3.078125
▁be 0.65625
▁put 4.84375
▁under 4.34765625
▁scr 3.947265625
ut 0.0004646778106689453
iny 0.0030384063720703125
▁at 3.45703125
▁the 0.708984375
▁annual 3.130859375
▁European 2.904296875
▁Society 1.2607421875
▁for 0.479736328125
▁Medical 0.074951171875
▁On 0.005527496337890625
col 0.007358551025390625
ogy 5.9604644775390625e-05
▁( 0.43896484375
ES 0.028961181640625
MO 0.0006861686706542969
) 0.043701171875
▁conference 1.2841796875
▁in 0.9736328125
▁Vienna 2.498046875
. 1.1923828125
▁This 2.982421875
▁highly 5.1484375
▁anticip 0.85498046875
ated 0.0008597373962402344
▁conference 1.6650390625
▁will 1.228515625
▁bring 2.533203125
▁together 0.07208251953125
▁leading 2.0625
▁exper 1.5888671875
ts 0.00012743473052978516
▁and 2.328125
▁research 1.0478515625
ers 0.01071929931640625
▁in 1.326171875
▁on 2.88671875
col 0.00920867919921875
ogy 1.2874603271484375e-05
▁to 1.447265625
▁evaluate 4.2265625
▁the 0.58935546875
▁latest 0.59521484375
▁adv 1.2626953125
anc 0.86181640625
ements 0.0004706382751464844
▁in 0.2445068359375
▁the 0.494873046875
▁field 0.1412353515625
. 0.779296875
<0x0A> 0.280029296875
Mar 0.892578125
im 0.001903533935546875
ast 0.00027060508728027344
at 0.0005335807800292969
, 1.0556640625
▁a 1.4599609375
▁novel 2.111328125
▁th 3.044921875
era 0.0218353271484375
pe 4.494190216064453e-05
ut 6.723403930664062e-05
ic 0.0007257461547851562
▁agent 1.01171875
, 0.7529296875
▁is 0.939453125
▁designed 1.640625
▁to 0.0185394287109375
▁in 1.8154296875
hib 0.0042572021484375
it 0.00016248226165771484
▁the 0.48779296875
▁activity 1.2626953125
▁of 0.0015716552734375
▁matrix 2.427734375
▁metal 0.00888824462890625
lo 0.00040411949157714844
prote 0.0113525390625
in 0.02850341796875
ases 0.25244140625
▁( 0.1473388671875
M 0.0059051513671875
MP 6.401538848876953e-05
s 0.037384033203125
), 0.1634521484375
▁which 1.3203125
▁play 1.8642578125
▁a 0.1827392578125
▁critical 1.541015625
▁role 0.0005855560302734375
▁in 0.0001590251922607422
▁tum 1.7822265625
or 0.2459716796875
▁invasion 2.060546875
▁and 0.1285400390625
▁met 0.07562255859375
ast 0.0002751350402832031
asis 0.01285552978515625
. 0.061798095703125
▁By 1.2041015625
▁target 1.2158203125
ing 0.00017964839935302734
▁this 3.8046875
▁key 1.6337890625
▁mechanism 2.130859375
, 0.2303466796875
▁Mar 0.0604248046875
im 0.0010251998901367188
ast 3.159046173095703e-05
at 0.00032448768615722656
▁a 5.16015625
ims 0.00963592529296875
▁to 0.00018107891082763672
▁restrict 7.16015625
▁the 0.44775390625
▁spread 0.5087890625
▁of 0.013916015625
▁cancer 0.05804443359375
▁cells 0.36572265625
, 1.2373046875
▁ultimately 3.20703125
▁providing 4.85546875
▁better 3.740234375
▁treatment 1.3583984375
▁out 0.8857421875
comes 1.728534698486328e-05
▁for 0.1612548828125
▁patients 0.161865234375
▁batt 6.11328125
ling 0.00039505958557128906
▁various 2.1640625
▁forms 1.0146484375
▁of 0.000537872314453125
▁cancer 0.2413330078125
. 0.09027099609375
<0x0A> 0.0804443359375
The 0.82421875
▁ES 1.2275390625
MO 0.00010323524475097656
▁conference 0.09259033203125
▁will 1.201171875
▁provide 0.80517578125
▁an 0.984375
▁ideal 1.3740234375
▁platform 0.12359619140625
▁for 0.12017822265625
▁British 0.7109375
▁Bi 0.002613067626953125
ote 0.0003485679626464844
ch 0.0034732818603515625
▁to 0.035003662109375
▁present 1.1796875
▁their 2.06640625
▁research 2.185546875
▁find 1.3349609375
ings 3.6954879760742188e-06
▁and 0.728515625
▁eng 2.103515625
age 0.0001327991485595703
▁in 0.998046875
▁meaning 2.064453125
ful 1.621246337890625e-05
▁discuss 0.3544921875
ions 8.344650268554688e-07
▁with 0.06805419921875
▁on 4.921875
col 0.41845703125
ogy 7.3909759521484375e-06
▁exper 0.193115234375
ts 2.7418136596679688e-06
▁from 1.119140625
▁around 0.312744140625
▁the 0.00634765625
▁world 0.07659912109375
. 0.00948333740234375
▁This 1.51953125
▁opportunity 3.38671875
▁will 0.85791015625
▁not 2.6015625
▁only 0.004009246826171875
▁allow 2.052734375
▁them 2.451171875
▁to 0.00042557716369628906
▁show 0.85791015625
case 0.00026607513427734375
▁the 0.55419921875
▁potential 0.455322265625
▁of 0.0523681640625
▁Mar 0.130859375
im 0.0010280609130859375
ast 0.0002689361572265625
at 0.00015223026275634766
▁but 0.994140625
▁also 0.1480712890625
▁receive 3.833984375
▁valuable 0.26708984375
▁feedback 0.09027099609375
▁and 0.49853515625
▁ins 0.52734375
ights 2.4080276489257812e-05
▁from 1.2490234375
▁the 0.96142578125
▁global 3.1796875
▁medical 3.7734375
▁community 0.052978515625
. 0.159912109375
<0x0A> 0.0215911865234375
The 1.3740234375
▁potential 5.0390625
▁of 0.58544921875
▁Mar 0.05987548828125
im 0.00084686279296875
ast 0.00011169910430908203
at 0.00013709068298339844
▁has 1.857421875
▁been 1.0703125
▁demonstrated 2.146484375
▁in 0.1317138671875
▁pre 2.037109375
cl 0.25244140625
in 1.430511474609375e-05
ical 3.4689903259277344e-05
▁studies 0.435546875
, 0.30224609375
▁exhib 8.8046875
iting 0.0006518363952636719
▁prom 1.953125
ising 0.00010693073272705078
▁results 0.6298828125
▁in 0.184326171875
▁in 1.8408203125
hib 0.006221771240234375
iting 0.004802703857421875
▁tum 0.900390625
or 0.0235595703125
▁growth 0.294189453125
▁and 0.2257080078125
▁mit 8.546875
ig 0.0006146430969238281
ating 0.0021572113037109375
▁cancer 2.509765625
▁cell 1.8193359375
▁invas 2.49609375
iveness 0.0843505859375
. 0.1341552734375
▁These 2.765625
▁pre 3.560546875
cl 1.150390625
in 0.00010418891906738281
ical 4.9233436584472656e-05
▁find 0.96240234375
ings 2.2649765014648438e-06
▁have 0.478759765625
▁p 2.44140625
aved 0.0003666877746582031
▁the 0.002986907958984375
▁way 0.0025959014892578125
▁for 0.00350189208984375
▁further 1.85546875
▁investig 3.669921875
ations 0.01097869873046875
▁in 1.439453125
▁clin 0.75341796875
ical 0.00048279762268066406
▁tri 0.09869384765625
als 3.2186508178710938e-06
, 0.2724609375
▁target 7.99609375
ing 0.020660400390625
▁specific 3.279296875
▁cancer 1.7431640625
▁types 0.239501953125
. 1.052734375
<0x0A> 0.2188720703125
D 5.34375
uring 0.294921875
▁the 0.0902099609375
▁conference 1.263671875
, 0.01020050048828125
▁British 0.19921875
▁Bi 0.0025691986083984375
ote 1.9550323486328125e-05
ch 0.0015153884887695312
▁will 0.330322265625
▁discuss 4.921875
▁the 0.489990234375
▁pre 3.94140625
lim 2.287109375
inary 0.0003020763397216797
▁results 0.75244140625
▁of 0.28369140625
▁their 1.2177734375
▁Ph 1.4580078125
ase 0.0011501312255859375
▁II 1.166015625
▁clin 0.9580078125
ical 0.00016069412231445312
▁trial 0.382080078125
, 0.8134765625
▁which 0.453125
▁focus 4.328125
es 0.0167236328125
▁on 0.00847625732421875
▁evalu 1.6982421875
ating 1.7881393432617188e-05
▁the 0.223876953125
▁safety 0.78564453125
▁and 0.11395263671875
▁effic 0.1756591796875
acy 4.291534423828125e-06
▁of 0.001819610595703125
▁Mar 0.043731689453125
im 0.0007433891296386719
ast 0.00019085407257080078
at 0.0001327991485595703
▁in 0.1580810546875
▁patients 0.57421875
▁with 0.055755615234375
▁advanced 0.94140625
▁breast 3.763671875
▁cancer 0.1363525390625
. 0.14794921875
▁This 1.3984375
▁trial 0.4091796875
▁a 2.89453125
ims 2.9087066650390625e-05
▁to 0.0016546249389648438
▁determine 1.486328125
▁the 0.405517578125
▁drug 3.7109375
' 0.90185546875
s 7.724761962890625e-05
▁ability 3.15625
▁to 0.001407623291015625
▁restrict 5.12109375
▁tum 0.5849609375
or 0.005615234375
▁pro 1.97265625
gression 0.0244140625
▁and 0.31396484375
▁improve 0.76513671875
▁patient 1.0263671875
▁out 0.337646484375
comes 6.091594696044922e-05
. 0.14599609375
▁If 6.32421875
▁the 1.712890625
▁results 0.91015625
▁prove 2.81640625
▁successful 1.17578125
, 0.0038890838623046875
▁the 1.3408203125
▁potential 3.998046875
▁imp 4.09765625
lications 0.0126190185546875
▁for 0.78759765625
▁breast 3.71875
▁cancer 0.01629638671875
▁treatment 0.4619140625
▁could 0.71435546875
▁be 0.0162506103515625
▁significant 0.9765625
. 0.4541015625
<0x0A> 0.0195465087890625
B 2.224609375
ey 2.16796875
ond 5.14984130859375e-05
▁breast 0.4365234375
▁cancer 0.00035381317138671875
, 0.0187835693359375
▁the 2.349609375
▁potential 2.041015625
▁for 3.509765625
▁Mar 0.0305938720703125
im 0.0007715225219726562
ast 0.00011706352233886719
at 0.0002181529998779297
▁to 0.44482421875
▁be 1.53125
▁effective 1.228515625
▁in 0.32958984375
▁other 0.64208984375
▁cancer 0.63818359375
▁types 0.0168609619140625
▁will 4.18359375
▁also 0.209716796875
▁be 0.006366729736328125
▁expl 1.2216796875
ored 6.794929504394531e-06
▁at 1.3984375
▁the 0.040985107421875
▁conference 0.2266845703125
. 0.0543212890625
▁British 2.404296875
▁Bi 0.0020999908447265625
ote 3.4332275390625e-05
ch 0.000537872314453125
▁has 1.669921875
▁initi 3.357421875
ated 0.0003018379211425781
▁pre 3.130859375
cl 0.181396484375
in 3.600120544433594e-05
ical 6.711483001708984e-05
▁studies 0.467041015625
▁to 1.076171875
▁evaluate 0.90380859375
▁the 0.11846923828125
▁drug 0.464599609375
' 0.01178741455078125
s 2.5510787963867188e-05
▁effic 0.87548828125
acy 7.987022399902344e-06
▁in 0.07391357421875
▁lung 3.9453125
, 0.83154296875
▁pan 1.8828125
cre 0.00012028217315673828
atic 0.0621337890625
, 0.09661865234375
▁and 0.2098388671875
▁col 1.109375
ore 0.0002149343490600586
ct 5.352497100830078e-05
al 2.384185791015625e-05
▁can 0.6328125
cers 1.3232231140136719e-05
. 0.9814453125
▁These 0.74267578125
▁on 3.5078125
going 0.0045318603515625
▁studies 0.91162109375
▁show 6.015625
▁promise 1.201171875
▁and 2.7578125
▁raise 5.703125
▁hopes 1.6279296875
▁of 2.482421875
▁a 1.9189453125
▁break 2.734375
through 3.170967102050781e-05
▁in 0.33642578125
▁tre 1.88671875
ating 1.2993812561035156e-05
▁various 2.423828125
▁challeng 7.0078125
ing 0.0001952648162841797
▁forms 2.2421875
▁of 0.00026798248291015625
▁cancer 0.0295867919921875
. 0.05078125
<0x0A> 0.00830841064453125
Wh 5.0078125
ile 0.0032367706298828125
▁significant 5.1640625
▁progress 0.44189453125
▁has 0.0269012451171875
▁been 0.02166748046875
▁made 0.0173492431640625
▁in 0.03973388671875
▁the 0.9287109375
▁fight 2.259765625
▁against 0.0002465248107910156
▁cancer 0.004833221435546875
, 0.05523681640625
▁there 0.873046875
▁is 0.2705078125
▁still 0.057830810546875
▁a 0.7734375
▁long 0.55419921875
▁way 0.07000732421875
▁to 0.0006198883056640625
▁go 9.28640365600586e-05
. 1.1064453125
▁Medical 6.62109375
▁profession 2.8046875
als 1.4185905456542969e-05
▁and 0.77001953125
▁research 0.262451171875
ers 0.0028057098388671875
▁are 1.8583984375
▁constantly 0.80859375
▁expl 3.73828125
oring 6.67572021484375e-06
▁new 0.1619873046875
▁a 1.5517578125
ven 7.021427154541016e-05
ues 1.3113021850585938e-06
▁and 1.947265625
▁innov 2.607421875
ative 0.40380859375
▁treat 1.4619140625
ments 5.364418029785156e-06
▁to 0.2958984375
▁improve 0.445068359375
▁patient 0.417724609375
▁out 0.024444580078125
comes 1.430511474609375e-05
. 0.333740234375
▁Mar 2.0703125
im 0.0005211830139160156
ast 6.961822509765625e-05
at 4.7087669372558594e-05
' 2.30859375
s 9.942054748535156e-05
▁appearance 8.5625
▁at 0.059356689453125
▁the 0.0841064453125
▁ES 0.072021484375
MO 4.1961669921875e-05
▁conference 0.0155487060546875
▁sign 4.9140625
ifies 0.00019371509552001953
▁a 0.5595703125
▁critical 3.15625
▁step 0.4423828125
▁in 0.6650390625
▁this 0.6767578125
▁journey 0.59814453125
, 0.701171875
▁as 1.943359375
▁it 0.278076171875
▁highlight 2.876953125
s 5.352497100830078e-05
▁the 0.10504150390625
▁potential 0.400390625
▁of 0.60986328125
▁target 1.734375
ed 1.52734375
▁th 2.095703125
era 5.602836608886719e-06
pe 2.86102294921875e-06
ut 4.76837158203125e-07
ic 1.234375
▁approaches 2.162109375
▁in 0.72216796875
▁comb 2.427734375
ating 0.081298828125
▁cancer 0.2393798828125
. 0.037445068359375
<0x0A> 0.0589599609375
With 4.21484375
▁the 0.947265625
▁presentation 5.875
▁and 3.857421875
▁review 6.60546875
▁of 0.03704833984375
▁Mar 1.5546875
im 0.000858306884765625
ast 0.00014078617095947266
at 0.000213623046875
▁at 1.1962890625
▁the 0.09564208984375
▁ES 0.4873046875
MO 6.568431854248047e-05
▁conference 0.0227508544921875
, 0.04193115234375
▁the 2.248046875
▁medical 1.6630859375
▁community 0.057373046875
▁eager 5.48828125
ly 0.0013580322265625
▁a 0.155029296875
wa 1.537799835205078e-05
its 2.384185791015625e-07
▁the 0.1688232421875
▁results 1.1533203125
▁of 0.49951171875
▁the 0.33203125
▁Ph 0.76513671875
ase 2.0265579223632812e-05
▁II 0.004772186279296875
▁clin 0.33056640625
ical 6.914138793945312e-05
▁trial 0.031280517578125
▁and 0.8779296875
▁the 0.5009765625
▁further 4.51171875
▁expl 2.4453125
oration 0.04376220703125
▁of 0.0210113525390625
▁its 2.171875
▁effic 1.5546875
acy 4.291534423828125e-06
▁in 0.04730224609375
▁various 0.89453125
▁cancer 0.06744384765625
▁types 0.00917816162109375
. 0.0055389404296875
▁The 1.265625
▁enthus 5.23828125
ias 0.01450347900390625
m 6.198883056640625e-06
▁surrounding 2.01953125
▁this 0.81884765625
▁novel 2.22265625
▁anti 2.66015625
- 6.783008575439453e-05
can 0.002941131591796875
cer 1.3113021850585938e-05
▁treatment 0.388671875
▁exempl 5.984375
ifies 0.00016629695892333984
▁the 0.01129150390625
▁rel 3.974609375
ent 3.814697265625e-06
less 3.254413604736328e-05
▁efforts 2.876953125
▁made 5.0546875
▁by 0.365966796875
▁British 2.93359375
▁Bi 0.002857208251953125
ote 2.9087066650390625e-05
ch 0.00267791748046875
▁and 0.355224609375
▁the 0.8759765625
▁wider 2.326171875
▁scientific 2.39453125
▁community 0.018096923828125
▁to 0.5322265625
▁bring 3.16796875
▁en 9.3515625
hanced 0.0304107666015625
▁treatment 0.97998046875
▁options 0.07891845703125
▁to 0.1275634765625
▁patients 0.50439453125
▁batt 0.9345703125
ling 0.00011646747589111328
▁cancer 0.286376953125
. 0.10546875
